Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: EXCRETION Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants

NCT06180954
View directory record Official record
Conditions
Healthy
Interventions
[14C]-LOXO-305, LOXO-305
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE

NCT01082146
View directory record Official record
Conditions
Pharmacokinetics, Metabolism
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 21, 2026, 7:14 AM EDT
Not listed Not applicable Interventional

Enuresis Alarm - Is a Manual Trigger System Beneficial?

NCT03522818
View directory record Official record
Conditions
Enuresis, Nocturnal
Interventions
Manual Trigger, Normal
Behavioral
Lead sponsor
Gina Lockwood
Other
Eligibility
5 Years to 15 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435

NCT05686096
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MYK-224
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 21, 2026, 7:14 AM EDT
Not listed No phase listed Observational

A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids

NCT00273559
View directory record Official record
Conditions
Kidney Diseases
Interventions
prednisone
Drug
Lead sponsor
Florida Hospital Transplant Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2008 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers

NCT03596632
View directory record Official record
Conditions
Healthy Participants
Interventions
Fenebrutinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

NCT00478725
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
GW786034, oral, GW786034, IV, GW786034, radiolabeled oral
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

NCT05961384
View directory record Official record
Conditions
Hypertension
Interventions
baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects

NCT01975636
View directory record Official record
Conditions
Metabolism and Elimination
Interventions
E2609
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 21, 2026, 7:14 AM EDT
Active, not recruiting Not applicable Interventional

Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

NCT04633811
View directory record Official record
Conditions
Kidney Stone
Interventions
Low Oxalate Diet before Weight Loss, Oral load of oxalate and sucralose before Weight Loss, Optifast VLCD Program, Optifast VLCD Transition Phase, Low Oxalate Diet after Weight Loss, Oral load of oxalate and sucralose after Weight Loss
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 21, 2026, 7:14 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Working Inside for Smoking Elimination

NCT01122589
View directory record Official record
Conditions
Cigarette Smoking, Tobacco Smoking
Interventions
Motivational Interviewing/CBT, CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)
Behavioral · Other
Lead sponsor
Memorial Hospital of Rhode Island
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Not applicable Interventional

Internet Intervention for Childhood Encopresis

NCT00767403
View directory record Official record
Conditions
Encopresis
Interventions
Internet Intervention + Stepped Care, Internet Intervention, Patient Education Website
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
5 Years to 12 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 4 Interventional

Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension

NCT00419796
View directory record Official record
Conditions
Osteoarthritis With Controlled Hypertension
Interventions
Lumiracoxib
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants

NCT02570373
View directory record Official record
Conditions
Healthy
Interventions
Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Not applicable Interventional

Fosrenol and Phosphorus Balance - Lanthanum Carbonate

NCT01581996
View directory record Official record
Conditions
Chronic Kidney Failure, End-stage Renal Disease, Disorders Associated With Peritoneal Dialysis
Interventions
lanthanum carbonate
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 7:14 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

NCT00721422
View directory record Official record
Conditions
Renal Insufficiency, Pharmacokinetics
Interventions
PD 0332334
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

NCT00148382
View directory record Official record
Conditions
Obesity
Interventions
ATL-962
Drug
Lead sponsor
Alizyme
Industry
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2007 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

NCT00472368
View directory record Official record
Conditions
Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

NCT07444268
View directory record Official record
Conditions
Advanced Hematologic Malignancies
Interventions
DSP-5336, [14C]-DSP-5336
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 7:14 AM EDT
Active, not recruiting Phase 4 Interventional Results available

Use of the LEVA® Pelvic Health System for Fecal Incontinence

NCT06152224
View directory record Official record
Conditions
Fecal Incontinence
Interventions
The Leva Pelvic Health System
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Not applicable Interventional Results available

Scheduled Awakenings for the Treatment of Nocturnal Enuresis

NCT03047720
View directory record Official record
Conditions
Nocturnal Enuresis
Interventions
Lully Sleep Guardian
Device
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 21, 2026, 7:14 AM EDT
Not listed Not applicable Interventional

Efficacy of (WaterWorks®)Douching Device for Elimination of Perceived Vaginal Odor Not Caused by BV or Vaginitis

NCT00417365
View directory record Official record
Conditions
Vaginal Odor
Interventions
WaterWorks Douching Device
Device
Lead sponsor
Abbott Research Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Aventura, Florida • Plantation, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2007 · Synced Oct 21, 2026, 7:14 AM EDT
Withdrawn Phase 4 Interventional

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

NCT04235049
View directory record Official record
Conditions
HCV Infection
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 21, 2026, 7:14 AM EDT